Serelaxin

Drug Profile

Serelaxin

Alternative Names: ConXn; Reasanz; Recombinant human relaxin H2; Recombinant relaxin; Relaxin; Relaxin H2; rhRlx; RLX-030; RLX-030A; SUN-Y8002

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Howard Florey Institute
  • Developer Corthera; Genentech; Novartis
  • Class Heart failure therapies; Peptide hormones
  • Mechanism of Action Peptide hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse scleroderma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Acute heart failure
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute heart failure
  • Phase II Chronic heart failure; Coronary artery disease; Liver cirrhosis; Portal hypertension
  • Discontinued Diffuse scleroderma; Female infertility; Fibrosis; Labour disorders; Labour induction; Peripheral arterial disorders; Preeclampsia; Pulmonary fibrosis; Pulmonary hypertension

Most Recent Events

  • 01 Feb 2016 Phase-II clinical trials in Chronic heart failure (Adjunctive treatment) in Switzerland (IV) (NCT02625922)
  • 01 Feb 2016 Novartis Pharmaceuticals Corporation initiates the phase II RELAX-Cardio trial for Chronic heart failure (Adjunctive treatment) in Germany (IV) (NCT02625922)
  • 11 Dec 2015 Novartis Pharmaceuticals Corporation plans the phase II RELAX-Cardio trial for Chronic heart failure (Adjunctive treatment) in Germany, Switzerland and United Kingdom (IV) (NCT02625922)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top